- Home
- GF vs HURA Comparison
GF vs HURA Comparison
Compare GF & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | GF | HURA |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.7M | 160.5M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | GF | HURA |
|---|---|---|
| Price | $11.44 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 22.6K | ★ 258.8K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | ★ 47.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.98 | $0.41 |
| 52 Week High | $12.49 | $3.43 |
Technical Indicators
Market Signals| Indicator | GF | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 48.18 |
| Support Level | $11.19 | $2.14 |
| Resistance Level | $11.70 | $2.20 |
| Average True Range (ATR) | 0.25 | 0.18 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 43.10 | 30.51 |
Price Performance
Historical ComparisonAbout GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investments includes investments in different sectors such as the industrials, information technology, materials, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.